Search

everythinglearnresearchcommunity

for

Search:↓

A user started taking oral minoxidil (2.5 mg daily) along with topical minoxidil, dutasteride, microneedling, and various supplements to improve hair growth and overall health. They are also focusing on weight loss, exercise, and better lifestyle habits.

The user shared their 6-month progress using 0.25 mg finasteride, topical minoxidil, and dermastamping, noting good results but experiencing increased sleepiness. Another user suggested minoxidil might be causing the sleepiness, and the original poster considered adjusting their treatment.

A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.

EDHARRINGTON's journey to regrow his hair using finasteride, topical minoxidil, and micro-needling treatments over 4 years, with others commenting their support and admiration for his results.

Rotenone, a natural plant extract, may promote hair growth by increasing LDH activity and blocking MPC in the scalp, but it carries risks due to its toxicity. The suggested formulation includes Barbasco extract, DMSO, propylene glycol or PEG-400, ethanol, and a carrier oil.

The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopecia areata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopecia areata, and the lack of results from using finasteride, dutasteride, and minoxidil.

A 32-year-old man has been treating his hair loss with daily oral finasteride (1.25g), twice-daily topical minoxidil, weekly ketoconazole 2% shampoo, and weekly microneedling for almost three months, with no side effects from finasteride. He started with a Hamilton Norwood scale rating of 5 and has seen improvement without experiencing pain by using a 0.8mm needle length for microneedling.

A 25-year-old male was initially prescribed finasteride, oral minoxidil, and topical minoxidil for hair loss but saw no improvement after a month. His doctor switched him to dutasteride, continued both minoxidil treatments, and added PRP therapy.

Mixing ground finasteride pills with Minoxidil for topical use, with concerns about effectiveness and side effects. Users suggest using professionally formulated topical finasteride instead.

The user is considering switching from 0.25 mg oral finasteride to a 0.3% topical finasteride solution to see if it's more effective for hair loss. They also inquire about using 2.5 mg oral minoxidil with a 6% topical minoxidil solution.

A 32-year-old man experienced positive hair regrowth after 4 months using 1.2mg finasteride and 3mg oral minoxidil, with no side effects. He used a chewable combo pill from Hims, noting minoxidil aids regrowth and finasteride maintains hair.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

A 21-year-old has mixed results after 11 months of using oral Minoxidil (2.5mg) and Finasteride (1mg) for hair loss. They recently added 1% Keto shampoo, dermaneedling, and increased Minoxidil dosage, and are considering a hair transplant for improved density and aesthetics.

The conversation discusses concerns about MVSupplements.com products, specifically the Min+Ru spray and GHK Serum, due to discrepancies in ingredient lists and recent poor feedback. Users also mention a price increase and one user reports no issues with the RU powder.

The user "Emotional_Fun4990" shared their progress after using 1mg Finasteride daily, 5% Minoxidil, and a 0.5mm Derma-roller twice a week for 2 months. They noticed additional hair growth below the hairline and on the neck. Other users provided positive comments and encouragement.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

A 28-year-old male started a hair loss treatment with 2.5mg oral minoxidil daily, 1mg finasteride every other day, and a 1.5mm dermaroller once a week. After two months, he believes he sees some progress.

A 20-year-old male experienced significant hair regrowth and reduced shedding after four months of using 2.5mg oral minoxidil, 1mg oral finasteride, and weekly 1.5mm derma stamping. He reported no side effects from the treatments and noted increased hair growth in other areas of his body.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

A user's successful 4-month hair growth progress using Hims spray with 6% Minoxidil, 0.3% Finasteride, and a .25mm dermaroller twice a week. The user applies the spray once a day and has not experienced any side effects.

The conversation is about a hair loss treatment regimen that does not include finasteride. Specific treatments used are not mentioned.

A 24-year-old user shared their 12-month progress using 1mg oral finasteride and 5mg oral minoxidil for hair loss, reporting significant improvement after initially starting with 2.5mg minoxidil. They experienced no side effects and noted thicker eyelashes, with results becoming noticeable around the 9th or 10th month.

A user shared their 20-week progress using topical minoxidil (5%) and finasteride (0.1%) with a 1mm dermastamp, showing significant hair regrowth from NW5 to between NW3V and NW4. They experienced no side effects and plan to update at 12 months.

The user is pleased with their hair growth results after using oral minoxidil (2.5mg) for 3 months and finasteride (1mg) for 4 months, despite experiencing significant shedding initially. They prefer oral treatments over topical due to convenience and concerns about toxicity to pets.

A man in his 50s, who has been on Finasteride for 15 years, is considering adding a custom topical Minoxidil blend to his treatment due to recent hairline recession. He questions whether the custom blend is more effective than generic Minoxidil, expresses concerns about shedding and body hair growth, and seeks advice on application timing with styling products and whether to pursue other treatments like PRP or laser.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

A 21-year-old shared a 7-month update on using 1mg finasteride and minoxidil for hair loss, reporting positive results with no side effects except watery semen. The user initially stopped minoxidil due to inconvenience but resumed it after shedding, and is satisfied with the progress despite some thinning at the crown.

The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.

A 27-year-old male is using minoxidil 5% nightly and alternating between three hair serums during the day, seeking advice on whether this routine is beneficial or overly complicated. Responses suggest simplifying the routine by focusing on minoxidil, possibly increasing its concentration, and considering finasteride or dutasteride instead of multiple serums.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.